DAWN

13.01

2.25% -0.30

Handel nachbörslich: 13.07 0.06 +0.46%

Day One Biopharmaceuticals Inc (DAWN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.31

Offen:

$13.51

24-Stunden-Volumen:

1.52M

Relative Volume:

1.47

Marktkapitalisierung:

$1.34B

Einnahmen:

Nettoeinkommen (Verlust:

$-167.48M

KGV:

-5.6565

EPS:

-2.3

Netto-Cashflow:

$-197.47M

1W Leistung:

-17.97%

1M Leistung:

-13.32%

6M Leistung:

-19.54%

1J Leistung:

+7.17%

1-Tages-Spanne:

$12.86

$13.76

1-Wochen-Bereich:

$12.86

$15.91

52-Wochen-Spanne:

$11.30

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Firmenname

Day One Biopharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

650 484-0899

Adresse

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Mitarbeiter

174

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

DAWN's Discussions on Twitter

Vergleichen Sie DAWN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DAWN	13.01	1.34B	0	-167.48M	-197.47M	-2.30
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-09	Bestätigt	Needham	Buy
2024-08-01	Hochstufung	BofA Securities	Underperform → Buy
2024-04-24	Bestätigt	Needham	Buy
2023-04-25	Herabstufung	BofA Securities	Buy → Underperform
2023-02-08	Eingeleitet	CapitalOne	Overweight
2023-02-03	Eingeleitet	Oppenheimer	Perform
2022-12-15	Eingeleitet	H.C. Wainwright	Buy
2022-12-14	Eingeleitet	Needham	Buy
2022-12-05	Eingeleitet	Goldman	Buy
2022-12-01	Eingeleitet	BofA Securities	Buy

Alle ansehen

Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten

11:35 AM

Short Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Rises By 12.8% - MarketBeat

11:35 AM

11:21 AM

First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq

11:21 AM

08:44 AM

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

08:44 AM

08:30 AM

Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan

08:30 AM

Nov 17, 2024

59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024

Nov 11, 2024

(DAWN) Trading Advice - Stock Traders Daily

Nov 11, 2024

TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat

Nov 09, 2024

Nov 07, 2024

FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com

Nov 07, 2024

Nov 06, 2024

Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - Yahoo Finance

Nov 06, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 06, 2024

Nov 05, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat

Nov 05, 2024

Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada

Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com

Nov 04, 2024

Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St

Nov 04, 2024

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance

Nov 04, 2024

Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat

Nov 04, 2024

Nov 03, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 03, 2024

Nov 01, 2024

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance

Nov 01, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024

Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks

Nov 01, 2024

Oct 31, 2024

(DAWN) Proactive Strategies - Stock Traders Daily

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat

Oct 31, 2024

Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph

Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 31, 2024

ChromaDex Q3 2024 Earnings Preview - MSN

Oct 31, 2024